Germline variation and risk of immune-related adverse events (irAEs): A real-world BioVU study

被引：0
|
作者：
Balko, Justin M.
Yao, Lydia
Zhang, Siwei
Fahey, Catherine
Haugh, Alexandra
Davis, Andrea
Mukherjee, Eric
Hammer, Christian
Phillips, Elizabeth J.
Bejan, Cosmin A.
Xu, Yaomin
Johnson, Douglas Buckner
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] UCSF Hem, Onc Fellowship, San Francisco, CA USA
[3] Univ Colorado, Denver, CO USA
[4] Genentech Inc, South San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10582
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Defining real-world criteria for immune-related adverse events (irAEs).
    Singh, Prabhsimranjot
    Brito, Amanda
    Abdulnour, Raja-Elie E.
    Grover, Shilpa
    Yenulevich, Eric
    Stuver, Sherri Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Real-world characterization of patients with cancer admitted with immune-related adverse events (irAEs).
    Eng, Lawson
    Chen, RuiQui
    Smith, Elliot Charles
    Chan, Sze Wah Samuel
    Hueniken, Katrina
    Brown, M. Catherine
    Majeed, Habeeb
    Ross, Kendra
    Gray, Diana
    Xu, Wei
    Hogg, David
    Sridhar, Srikala S.
    Sacher, Adrian G.
    Leighl, Natasha B.
    Krzyzanowska, Monika K.
    Liu, Geoffrey
    Butler, Marcus O.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [3] Evaluating immune-related adverse events (irAEs) in a real-world cohort with lung cancer receiving immunotherapy
    Hu, Xiao
    Pan, Stacey
    Salei, Yana V.
    Lin, Jeffrey H.
    Parsons, Susan K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E32 - E32
  • [4] Real-world management of immune-related adverse events in the community setting
    Johnson, D. B.
    Bruno, D.
    Rioth, M.
    Zhang, C.
    Palaia, J.
    Pisupati, R.
    Bond, C.
    Rosenblatt, L. C.
    Broome, R. G.
    Teka, M.
    Kluger, H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1268 - S1269
  • [5] Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
    Batista-Duharte, Alexander
    Alino, Salvador F. F.
    FRONTIERS IN ALLERGY, 2023, 4
  • [6] Efficacy and hepatotoxicity of Infliximab in resolving steroid-refractory immune-related adverse events (irAEs) in a real-world setting.
    Muniz, Thiago Pimentel
    Araujo, Daniel Vilarim
    Yang, Anjie
    Sorotsky, Hadas
    Keshavarzi, Sareh
    Butler, Marcus O.
    Saibil, Samuel
    Spreafico, Anna
    Hogg, David
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
    Knox, A.
    Cloney, T.
    Janssen, H.
    Solomon, B.
    Alexander, M.
    John, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S1684 - S1684
  • [8] Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events
    Teimouri, Arezou
    Minard, Laura, V
    Scott, Samantha N.
    Daniels, Amanda
    Snow, Stephanie
    CURRENT ONCOLOGY, 2022, 29 (05) : 3104 - 3117
  • [9] Acknowledging and addressing real-world challenges to treating immune-related adverse events
    von Itzstein, Mitchell S.
    Gerber, David E.
    Bermas, Bonnie L.
    Meara, Alexa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07)
  • [10] Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) in a real-world analysis: A risk prediction nomogram
    Ferro, A.
    Girardi, F.
    Pretelli, G.
    Mulargiu, C.
    Resi, M. V.
    Benetti, B.
    Marinato, G. M.
    Lorenzi, M.
    Dal Maso, A.
    Frega, S.
    Pasello, G.
    Guarneri, V.
    Bonanno, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1269 - S1270
12345